Nurhan Demir

Nurhan Demir

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2020 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
NDNurhan Demir
Nurhan Demir
NENazım Ekin
Nazım Ekin
MTMurat Torgutalp
Murat Torgutalp
SWStaffan Wahlin
Staffan Wahlin
CECumali Efe
Cumali Efe
Background/Aims: Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) are the 3 main autoimmune liver diseases (AILDs). The epidemiology of AILD in Turkey is not known. To determine the scientific status, we performed a scientometric analysis of AILD-related original articles that originated from Turkey. Materials and Methods: We searched the Web of Science database, the Science Citation Index Expanded (SCI-E), and the Social Sciences Citation Index (SSCI) by using the keywords “autoimmune hepatitis,” “primary biliary cholangitis/primary biliary cirrhosis,” and “primary sclerosing cholangitis” in conjunction with “Turkey.” A scientometric analysis was done on the search results. Results: We identified 117 AILD-related papers that were published in Turkey from 1997 to 2019. Among these, 70 case reports, letters, and reviews and 2 original articles that were not cited in SCI-E/SSCI were excluded. The remaining 45 original articles were further analyzed. These studies were related to AIH (n=22), PBC (n=7), PSC (n=9), PBC-AIH overlap (n=5), and others (n=2). Four of the publications originated in pediatric settings; 9 of 45 papers were published from 1997 to 2008 and 36 papers were published from 2009 to 2019. Most papers (75%) were reported from 5 centers; 9 papers (20%) were published in journals with an impact factor of 3 or higher. Conclusion: The overall number and quality of AILD-related papers in Turkey are unexpectedly low, although a number of papers have received considerable international recognition. More epidemiologic, prospective, and multicenter research projects are warranted to advance AILD knowledge and to produce high-quality research from Turkey.

1 January 2022 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
NDNurhan Demir
Nurhan Demir
BYBilgehan Yüzbasıoglu
Bilgehan Yüzbasıoglu
TCTuran Calhan
Turan Calhan
SOSavas Ozturk
Savas Ozturk
Introduction. The fibrosis 4 (FIB‐4) index was developed to predict advanced fibrosis in patients with liver disease. We aimed to evaluate the association of FIB‐4 with risk factors for progression to critical illness in middle‐aged patients hospitalized for coronavirus disease 2019 (COVID‐19). Method. We included patients aged 35–65 years who were hospitalized following a positive RT‐PCR SARS‐Cov‐2 test in a tertiary hospital. All data were obtained from the medical records of the patients during the first admission to the hospital. The FIB‐4 index was calculated according to the equation (age (years) x AST (IU/L)/platelet count (109/L)/√ALT (IU/L)). The FIB‐4 index was divided into three categories according to the score categorisation: 2.67 = high risk. Results. A total of 619 confirmed COVID‐19 patients (mean age = 52 yrs.) were included in this study; 37 (6.0%) were admitted to the intensive care unit (ICU), of which 44% were intubated and eight (1.3%) patients died during follow‐up. The results of patients with high FIB‐4 scores were compared with those with low FIB‐4 scores. In patients with high FIB‐4 scores, male gender, and advanced age, decreased neutrophil, lymphocyte, thrombocyte, and albumin counts, elevated AST, LDH, CK, ferritin, CRP, and D‐dimer, and low GFR were the high‐risk factors for critical illness. Additionally, the number of patients referred to ICU with high FIB‐4 who died had higher scores than from those with low scores. Conclusion. The FIB‐4 index derived from baseline data obtained during hospitalisation can be used as a simple, inexpensive, and straightforward indicator to predict ICU requirement and/or death in middle‐aged hospitalized COVID‐19 patients.

19 September 2023 in Bagcilar Medical Bulletin
Verified
Journal Article
Closed access
NDNurhan Demir
Nurhan Demir
BYBilgehan Yüzbaşıoğlu
Bilgehan Yüzbaşıoğlu
EKEmine Kanatsız
Emine Kanatsız
SBSaime Gül Barut
Saime Gül Barut

16 July 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
Handan TokmakHandan Tokmak
Handan Tokmak
NDNurhan Demir
Nurhan Demir
HCHazal Cansu Culpan
Hazal Cansu Culpan
Background: The accurate prediction of pathological complete response (pCR) following total neoadjuvant therapy (TNT) is crucial for optimising treatment protocols in locally advanced rectal cancer (LARC). Although conventional imaging techniques such as MRI show limitations in assessing treatment response, metabolic imaging utilising 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET-CT) provides distinctive information by quantifying tumour glycolytic activity. This study investigates the predictive value of sequential 18F-FDG PET-CT parameters, focusing on Total Lesion Glycolysis (TLG), in predicting pCR after TNT. Methods: We conducted a retrospective analysis of 33 LARC patients (T3–4/N0–1) treated with TNT (neoadjuvant-chemoradiation followed by consolidation FOLFOX chemotherapy). Sequential PET-CT scans were performed at baseline, interim (after 4 cycles of FOLFOX), and post-TNT. Metabolic parameters, including maximum standardised uptake value (SUVmax) and TLG, were measured. Receiver operating characteristic (ROC) analysis assessed the predictive performance of these parameters for pCR. Results: The pCR rate was 21.2% (7/33). Post-TNT TLG ≤ 10 demonstrated excellent predictive accuracy for pCR (AUC 0.887, 92.3% sensitivity, 85.7% specificity, and 96.0% PPV), outperforming SUVmax (AUC 0.843). Interim TLG ≤ 10 also showed a strong predictive value (AUC 0.824, 100% sensitivity, and 71.4% specificity). Conclusions: TLG may serve as a reliable metabolic biomarker for predicting pathologic complete response (pCR) after total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC). Its inclusion in clinical decision-making could improve patient selection for organ preservation strategies, thereby reducing the need for unnecessary surgeries in the future. However, given that the study is based on a small retrospective design, the findings should be interpreted with caution and used alongside other decision-making tools until more comprehensive data are collected from larger studies.
1

21 May 2020 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
NDNurhan Demir
Nurhan Demir
CECumali Efe
Cumali Efe
ŞÖŞehmus Ölmez
Şehmus Ölmez
AOArzu Onur
Arzu Onur
EYEric M. Yoshida
Eric M. Yoshida
Background and Aim: Antibodies to soluble liver antigen (anti-SLA) and anti-mitochondrial autoantibodies (AMA) are two specific serological markers of autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). They are rarely detected in the sera of patients with non-liver autoimmune disorders. Materials and Methods: The biochemical, serological, and histological findings of two celiac disease (CD) patients who were seropositive for anti-SLA and/or AMA were evaluated. Results: The data of two female patients who were 28 and 34 years old at the time of CD diagnosis were analyzed. The first patient presented with elevated liver function tests (LFTs) and immunoglobulin (Ig) G values. She was seropositive for both anti-SLA and AMA. A liver biopsy suggested features of AIH but no bile duct injury was noted. In addition to a gluten-free diet (GFD), immunosuppressive therapy was administered to normalize the LFTs. The second patient presented with elevated LFTs, a high IgG level, and a positive anti-SLA finding. A GFD was initiated, which resulted in an excellent clinical and biochemical response. Seropositivity for AMA in the first patient and anti-SLA in the second patient remained unchanged during follow-up but neither patient developed primary biliary cholangitis or AIH. Conclusion: Despite the high specificity of anti-SLA and AMA, these autoantibodies can be detected in CD without having any clinical relevance.

23 March 2023 in Medical Journal of Bakırkoy
Verified
Journal Article
Closed access
NDNurhan Demir
Nurhan Demir
AGAlper Güllüoğlu
Alper Güllüoğlu